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ABSTRACT
Coupled bone turnover is directed by the expression of receptor-activated NF-B ligand (RANKL) and its
decoy receptor, osteoprotegerin (OPG). Proinflammatory cytokines, such as interleukin-1 (IL-1) and tu-
mor necrosis factor- (TNF-) induce RANKL expression in bone marrow stromal cells. Here, we report that
IL-1 and TNF--induced RANKL requires p38 mitogen-activating protein kinase (MAPK) pathway acti-
vation for maximal expression. Real-time PCR was used to assess the p38 contribution toward IL-1 and
TNF--induced RANKL mRNA expression. Steady-state RANKL RNA levels were increased approximately
17-fold by IL-1 treatment and subsequently reduced 70%–90% when p38 MAPK was inhibited with
SB203580. RANKL mRNA stability data indicated that p38 MAPK did not alter the rate of mRNA decay in
IL-1-induced cells. Using a RANKL-luciferase cell line receptor containing a 120-kB segment of the 5 flank-
ing region of the RANKL gene, reporter expression was stimulated 4–5-fold by IL-1 or TNF- treatment.
IL-1-induced RANKL reporter expression was completely blocked with specific p38 inhibitors as well as
dominant negative mutant constructs of MAPK kinase-3 and -6. In addition, blocking p38 signaling in bone
marrow stromal cells partially inhibited IL-1 and TNF--induced osteoclastogenesis in vitro. Results from
these studies indicate that p38 MAPK is a major signaling pathway involved in IL-1 and TNF--induced
RANKL expression in bone marrow stromal cells.
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INTRODUCTION
EXCESSIVE OSTEOCLAST-MEDIATED bone resorption is a common feature of chronic inflammatory processes, for ex-
ample, periodonitis, rheumatoid arthritis, and failing joint pros-
theses. Several lines of evidence indicate that cytokine net-
working and crosstalk between stromal/osteoblastic cells and
monocyte/osteoclast progenitor cells dictate cellular responses
involved in bone remodeling. Several mediators of bone re-
sorption and remodeling have been identified in response to
such proinflammatory cytokines, as interleukin-1 (IL-1), bac-
terial lipopolysaccharide (LPS), and other bone-resorptive
agents. Bone marrow stromal cells respond to these agents and
directly or indirectly secrete various cytokines that activate re-
ceptor activator of NF-B ligand (RANKL), resulting in en-
hanced osteoclastogenesis.1,2
Bone marrow stromal cell-derived RANKL is essential for
osteoclastic differentiation of monocyte precursor cells into ma-
ture multinucleated osteoclasts in the presence of macrophage
colony-stimulating factor (M-CSF).3,4 RANKL is highly ex-
pressed on the surface of bone marrow stromal cells and pre-
osteoblasts in the areas of excessive osteolysis and trabecular
bone remodeling.5 RANKL expression is upregulated in os-
teoblasts or stromal cells by IL-1, IL-6 (in the presence of 
soluble IL-6 receptor), tumor necrosis factor- (TNF-), pros-
taglandin E2 (PGE2), parathyroid hormone (PTH), 1,25-dihy-
droxyvitamin D3, and others.1,6–8 Through interactions with its
cognate receptor (RANK) on osteoclast progenitor cells,
RANKL induces differentiation and maturation of osteoclasts.
Balancing this system is the decoy receptor, osteoprotegerin
(OPG), a soluble member of the tumor necrosis family capable
of binding to RANKL, thus decreasing RANKL functional ac-
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tivity.9 It is the ratio of RANKL/OPG that eventually deter-
mines bone turnover.10
Proinflammatory cytokines stimulate multiple intracellular
signaling pathways, including the p38 mitogen-activating pro-
tein kinase (MAPK) pathways, NF-B pathway, extracellular
signal-regulated kinase (ERK) pathway, and stress-activated
protein kinase/c-Jun N-terminal kinase (SAPK/JNK) pathway
(SAPK/JNK).11,12 Although much attention has been focused
on the NF-B pathway of cytokine gene activation, more re-
cent study has addressed JNK and p38 MAPK during inflam-
mation and environmental stress-induced signaling.13 The p38
kinases constitute a distinct MAPK subfamily that plays a role
in adaptation, homeostasis, and stress responses.14 Of the iden-
tified four splice variants, p38 MAPK is the best character-
ized and perhaps the most relevant kinase involved in inflam-
matory responses.15,16 The essential role of p38 MAPK in
RANKL-induced osteoclastogenesis has been elucidated in
macrophage/osteoclast precursor cells,17 although the role of
p38 regulation in stromal/osteoblastic-derived RANKL expres-
sion has been addressed only recently.7,18,19 In this study, the
role of p38 signaling was investigated during cytokine-induced
RANKL expression in bone marrow stromal cells. Our results
indicate that MKK3/6-p38 signaling is necessary for IL-1-in-
duced RANKL expression involving a transcriptional mecha-
nism that does not require the proximal RANKL promoter rel-
ative to the transcriptional start site.
MATERIALS AND METHODS
Tissue culture of murine ST-2, UAMS-32P cells
ST-2 bone marrow stromal cells were obtained from Riken
(Wako, Japan). UAMS-32P bone marrow stromal cells were ob-
tained from Dr. Charles O’Brien (University of Arkansas).
UAMS-32P cell lines express RANKL in response to
1,25(OH)2D3 and constitutively express M-CSF.20 Cells were
cultured in -MEM medium (Life Technologies, Gaithersburg,
MD) supplemented with 10% fetal bovine serum (FBS) (Sigma,
St. Louis, MO). Cells were routinely serum starved in 0.3% FBS-
containing medium for 6–8 h prior to cytokine stimulation.
Real-time PCR analysis
Total RNA (5 g) from ST-2 and UAMS-32P cells was iso-
lated using Trizol reagent (Invitrogen, Carlsbad, CA) and used
for cDNA synthesis with oligo(dT) 12-18 primers and Super-
script II (RNAse H) (Invitrogen) in reverse transcription (RT)
reactions. Real-time PCR was performed with 2 L of the RT
preparation using Taq polymerase (Invitrogen) and primers spe-
cific for mouse RANKL and GAPDH cDNAs. RANKL and
GAPDH were amplified for 50 cycles using the BioRad’s
SYBR Green Supermix kit (Bio-Rad, Hercules, CA) following
the manufacturer’s instructions. Real-time PCR primer se-
quences were as follows: RANKL, forward: 5-agcaacg-
gaaaactaagggt-3, reverse: 5-cccccaacatttatggaata-3; GAPDH,
forward: 5-caaagccagagtccttcaga-3, and reverse: 5-gatg-
gtcttggtccttagcc-3. Threshold values were assigned by the 
iCycler program (Bio-Rad) and used with amplification effi-
ciencies to calculate RANKL expression. Q-gene (www.
biotechniques.com/softlib/qgene.html) quantitative software
was used to analyze gene expression based on cycle threshold
values normalized to GAPDH expression. Real-time PCR prod-
ucts were also verified through electrophoresis on 2% agarose
gel and visualized using ethidium bromide staining to verify
authenticity.
mRNA stability experiments
To determine the relative role of p38 MAPK on IL-1-in-
duced RANKL mRNA stability, the rate of RANKL mRNA de-
cay was determined in the presence and absence of the p38 in-
hibitor, SB203580. Actinomycin D (ActD) was used in the
experiments to arrest transcription as described previously.21
Briefly, ST-2 and UAMS-32P cells were pretreated with
SB203580 (2 M) for 45 min, then treated with IL-1 for 16–18
h. Subsequently, ActD (2 M) was added to prevent further
transcription. Total RNA was harvested and analyzed by real-
time RT-PCR as described 0–8 h post-ActD addition.
RT-PCR analysis
Total RNA (5 g) from ST-2 and UAMS-32P cells was iso-
lated using Trizol reagent and used for cDNA synthesis with
oligo(dT) 12-18 primers and Superscript II (RNAse H) in RT
reactions. RT product (2 L) was used as a template for PCR
amplification of RANKL and GAPDH gene products. Primers
sequences used were: RANKL [AF_019048, forward: 5-
cagcactcactgcttttatagaatcc-3, reverse: 5-agctgaagatagtctgtag-
gtacgc-3; GAPDH [NM_002046], forward: 5-caccatggagaag-
gccgggg 3, reverse: 5-gacggacacattggggtag-3. RT-PCR
products were separated and analyzed by gel electrophoresis.
Resulting images were captured using the Gel-Doc (Bio-Rad)
imaging system equipped with UV light and a gel scanner. PCR
results were quantitated using Bio-Rad’s PhosphoImager sys-
tem and Quantity One software to assess relative differences.
Immunoblot analysis
UAMS-32P cells were exposed to SB203580 (5 M) for
30 min, then stimulated with IL-1 (5 ng/mL) for 72 h. Cells
were rinsed with ice-cold phosphate-buffered saline (PBS), then
lysed in SDS-PAGE buffer (Bio-Rad). Protein concentrations
were measured by Bradford’s method (Bio-Rad). Each sample
(10 g) was electrophoresed on 10% denatured SDS-PAGE
gels and electrotransferred to nitrocellulose membranes (Bio-
Rad). For detection of membrane-bound RANKL expression,
whole cell lysates were probed with 0.2 g/mL rabbit antimouse
RANKL IgG (R&D Systems, Minneapolis, MN) and detected
using horseradish peroxidase (HRP)-conjugated secondary an-
tibodies and LumniGlo (Cell Signaling Technologies, Beverly,
MA) chemiluminescence detection. Anti-GAPDH antibody
(Chemicon, Temecula, CA) was used to verify even protein
loading transferred to membranes.
RANKL-luciferase reporter cell line
RANKL-luc cells (derived from UAMS-32P cells) were
generated through stable transfection of a bacterial artificial
chromosome (BAC) clone containing the entire exonic/in-
tronic sequence of the murine RANKL gene along with the
5 flanking region (120 kb). The 3-UTR of the RANKL
gene was removed in the BAC clone and replaced with a lu-
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ciferase reporter (gift from C. O’Brien, University of
Arkansas22). The dual luciferase assay kit (Promega, Madi-
son, WI) was used to measure RANKL-luc activity in total
protein normalized samples (LMaxII, Molecular Devices,
Menlo Park, CA). Luciferase activity was measured in re-
sponse to constructs harboring upstream constitutively active
genes encoding MKK6b and MKK3b23 (a gift from Bhat,
University of South Carolina). In other studies, MKK6 and
MKK3 dominate negative (dn) constructs (a gift from J. Han,
Scripps Institute) were transfected, and IL-1 or TNF-
was added 24 h posttransfection to stimulate RANKL-luc
cells.
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FIG. 1. IL-1 and TNF--induced RANKL expression in different bone marrow stromal cells is regulated by p38 MAPK. (A)
ST-2 and (B) UAMS-32P cells were treated with 10 M SB203580 (SB) and stimulated with 1 ng/mL IL-1 or 5 ng/mL TNF-
 for 18 h. Real-time PCR with cytokine-induced RANKL steady-state mRNA expression. Values expressed represent threshold
crossing values normalized to GAPDH (n  4 for each). IL-1 and TNF- stimulated RANKL expression: **p  0.0001 vs.
control and *p  0.05 vs. control, respectively. SB203580 decreased RANKL expression: **p  0.0001 for IL-1 vs. SB/IL-1




UAMS-32P bone marrow stromal cells (1  104) were cul-
tured in 6-well dishes for 24 h, deinduced for 6 h in 0.3% serum
containing medium, and stimulated for 72 h as described for im-
munoblot analysis. Following the 72-h incubation period, stromal
cells were washed extensively with PBS, and RAW264.7 macro-
phages were added at 2  104 cells/well and cocultured with ad-
herent stromal cells in -MEM containing 10% serum for 6 days,
with the medium replaced on day 3. For control cultures,
RAW264.7 cells only were cultured with or without RANKL (50
ng/mL). Following coculture, cells were cytochemically stained
for tartrate-resistant acid phosphatase (TRAP), using a commer-
cially available kit (Sigma). TRAP-positive multinucleated cells
containing more than three nuclei were identified as osteoclasts
and counted by light microscopy. All experiments were carried
out three times in triplicate measurements. Images of cultured cells
were digitally captured using a Nikon TS100 inverted scope and
Nikon 5.1 megapixel camera (Nikon, Tokyo, Japan).
Statistical analysis
Pairwise comparisons between experimental groups were
performed using the Student’s t-test with Welch’s correction
for unequal variances or one-way ANOVA analysis where in-
dicated. Significance level was set at 5% unless otherwise
noted. All calculations were performed using Prism 4 software
(GraphPad, Inc., San Diego, CA).
RESULTS
SB203580 inhibits IL-1 and TNF-induced 
RANKL mRNA steady-state levels in bone 
marrow stromal cells
Real-time PCR was used to quantitate stromal cell-derived
RANKL expression. By comparison of normalized threshold
crossing values (Fig. 1), results indicate that steady-state RNA
levels were increased approximately 17-fold by IL-1 treatment
(p  0.0001) and subsequently reduced 70%–90% by pretreat-
ment with SB203580 (Fig. 1) (p  0.0001 in ST-2 cells and
p  0.05 in UMAS-32P cells). Inhibition of TNF--stimulated
RANKL expression was observed following addition of a p38
inhibitor; however, the level of stimulation with TNF- was
consistently less than the stimulation observed with IL-1 in
both ST-2 and UAMS-32P cells (p  0.05 vs. control).
Inhibition of p38 MAPK decreases IL-1 and TNF--
induced membrane-bound RANKL expression
Immunoblot analysis was used to determine if p38 MAPK
signaling affected IL-1 or TNF-induced RANKL protein ex-
pression. Whole cell extracts from cells stimulated for 72 h in
the presence or absence of the p38 inhibitor indicated that IL-
1-induced RANKL expression was partially inhibited by
SB203580 (Fig. 2A). A graphic depiction of RANKL:GAPDH
on the immunoblot is shown in Figure 2B. Data from three ex-
periments indicated significant inhibition of IL-1-stimulated
RANKL protein expression in the presence of the p38 inhibi-
tor (p  0.01).
p38 MAPK does not increase RANKL mRNA half-life
p38 signaling is a critical determinant of the mRNA stabil-
ity of several cytokine and chemokine mRNAs.24 To determine
if p38 MAPK was involved in IL-1-induced RANKL stabil-
ity, mRNA decay experiments were performed using ActD to
arrest transcription. Following stimulation with IL-1 with or
without SB203580, ActD was added to ST-2 and UAMS-32P
cells for the indicated times. RANKL mRNA levels were ana-
lyzed by real-time RT-PCR, as in Figure 1. Mean results of two
independent experiments yielding identical results are presented
in Figure 3. Following treatment with SB203580, no significant
alteration in mean rate of mRNA decay was observed in IL-
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FIG. 2. Membrane-bound RANKL protein expression in bone marrow stromal cells is dependent on p38 signaling. (A) UAMS-
32P cells were stimulated with 1 ng/mL IL-1 in the presence or absence of 10 M SB203580 for 72 h. Medium with new cy-
tokines and p38 inhibitors was added after 36 h of culture. Immunoblot analysis of whole cell lysates indicates that membrane-
bound RANKL protein expression is increased by IL-1 treatment (lane 2) but partially inhibited in the presence of SB203580.
(B) Graphic representation of data in A. *p  0.05 for IL-1-stimulated RANKL vs. control; **p  0.01 for SB/IL-1 vs. IL-
1 only.
A B
1-treated cells. Very little RANKL mRNA could be measured
in untreated and SB203580-treated cultures (n  2) (data not
shown). Results indicate that RANKL mRNA half-life is 3.8
h in ST2 cells and 1 h in UAMS-32P cells following IL-1
stimulation.
IL-1-induced RANKL-luc reporter cells through
MKK3/6-p38 MAPK signaling
To determine if p38 MAPK exerts its regulatory effect on
elements other than the proximal promoter of RANKL, a re-
porter cell line containing a 120-kb region of the murine
RANKL 5-flanking region plus the entire coding sequence
along with a luciferase reporter gene was inserted into the 3-
UTR of this construct (generous gift from C. O’Brien, Univer-
sity of Arkansas). With this mRANKL reporter cell line
(RANKL-luc), a 4.5-fold increase in luciferase reporter activ-
ity was demonstrated after 18 h of stimulation with IL-1 or
TNF- (Fig. 4A). Pretreatment with SB203580 completely in-
hibited IL-1 or TNF--stimulated RANKL-luc reporter ex-
pression (IL-1, p  0.0007; TNF-, p  0.0001). To confirm
the role of p38 signaling in IL-1 or TNF--induced RANKL
expression, RANKL-luc cells were transfected with MKK3/6
dn constructs to block p38 signaling and then stimulated with
IL-1 to stimulate RANKL-luc cells. In Figure 4B, both
MKK3dn and MKK6dn completely inhibited IL-1-stimulated
RANKL-luc reporter expression (p  0.0004, IL-1  IL-
1/MKK3b; p  0.0003, IL-1  IL-1/MKK6b). Mock control
(empty vector) did not have any effect on RANKL-luc expres-
sion. To clarify the role of p38 involvement with RANKL
RANKL-luc expression, MKK3bE or MKK6bE both active mu-
tants of the upstream p38 activators (MKK3 or MKK6) were
transfected into RANKL-luc reporter cell lines (Fig. 4C). Us-
ing these vectors, a modest but significant enhancement of
RANKL-luc reporter expression was observed, indicating p38
signaling activates RANKL reporter cell line expression (p 
0.005, mock  MKK3ca; p  0.012, mock  MKK6ca).
MKK3/6dn constructs partially block cytokine-induced
endogenous RANKL expression
As MKK3dn and MKK6dn transfected plasmids were able
to partially attenuate RANKL-luc expression, it was important
to determine if similar effects were observed with endogenous
RANKL mRNA expression. UAMS-32P cells were transfected
with MKK3/6dn constructs and 24 h later stimulated with IL-
1 for an additional 18-h period. Data presented in Figure 5 in-
dicate that both MKK3dn and MKK6dn partially inhibit both
IL-1-induced and TNF--induced RANKL expression. Sig-
nificant levels of inhibition were observed with MKK3dn and
MKK6dn blocking IL-1-stimulated RANKL in ST-2 cells
(p  0.01) and TNF--induced RANKL expression (p  0.01,
MKK3dn/TNF vs. TNF only; p  0.001, MKK6dn/TNF vs.
TNF only). In UAMS-32P cells, significant inhibition was ob-
served only with MKK3dn blocking TNF--induced RANKL
mRNA expression (p  0.05), although the trend was observed
with IL-1-treated cells as well.
Inhibition of p38 signaling partially blocks IL-1 and
TNF--induced osteoclastogenesis
To better understand the significance of p38 signaling in
RANKL expression, we performed mouse osteoclastogenesis
assays. Using the coculture design, we stimulated stromal cells
with cytokines for 72 h, changing medium with fresh reagents
after 36 h. After extensive rinsing of stromal cells, RAW264.7
macrophages were added for an additional 5–6 days of culture.
In these assays, we show that IL-1 and TNF- both induced
TRAP-positive cell formation in coculture (Fig. 6). Treatment
of bone marrow stromal cells with SB203580 (10 M) reduced
the numbers of IL-1 and TNF--induced TRAP-positive cells
formed in culture. Unstimulated UAMS-32P cells minimally
supported osteoclast formation. In additional studies, condi-
tioned medium from treated stromal cells did not induce os-
teoclast formation (data not shown), indicating that most
RANKL expression was membrane bound and not secreted.
RAW cells stimulated with exogenous RANKL consistently
stimulated osteoclast formation (TRAP cell formation) better
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FIG. 3. p38 MAPK does not affect RANKL mRNA stability
in stimulated cells. (A) ST-2 or (B) UAMS-32P cells were
treated as in Figure 1. In the last 4–8 h, cells were treated with
2 M ActD to arrest transcription. Total RNA was analyzed by
real-time PCR as described in Figure 1. Mean decay values are
expressed as a percentage of RANKL mRNA expression nor-
malized to GAPDH at 0 time in ST-2 cells (A) or UMAS-32





FIG. 4. RANKL-luc reporter cell lines are regulated by p38 MAPK similar to endogenous gene expression. (A) RANKL-luc re-
porter cells were treated with SB203580 (10 M) for 30 min and then stimulated for 18 h with IL-1 (1 ng/mL) or TNF- (5
ng/mL) or stimulated only with cytokines. Cell lysates were harvested and used to determine luciferase activity in RANKL-luc re-
porter cells. Mean luciferase activity normalized to total protein is shown (n  4). SB203580 significantly blocked IL-1 and TNF-
-induced RANKL-luc activity. **IL-1, p  0.0007; TNF-, p  0.0001. (B) RANKL-luc reporter cells were transiently trans-
fected with MKK3dn or MKK6dn and then stimulated with IL-1 (n  3). MKK3dn or MKK6dn constructs significantly blocked
IL-1-induced RANKL luciferase reporter expression. **p  0.0004, IL-1  IL-1/MKK3b; p  0.0003, IL-1  IL-1/MKK6b.
(C) Transiently transfected MKK3 or MKK6 constitutively active (ca) vectors increase RANKL 5 flanking region reporter ex-




than IL-1 or TNF- in all experiments. Similar data were ob-
tained with ST-2 cells, although the number of osteoclasts
formed was significantly less than that observed with UAMS-
32P cells (data not shown).
DISCUSSION
The crucial role of RANKL in osteoclastogenesis has been
clearly demonstrated in RANKL-deficient murine studies.25,26
Stromal/osteoblast-derived RANKL expression is a key com-
ponent leading toward osteoclastogenesis. This fact is high-
lighted by studies in which osteoclasts were not formed when
osteoblasts from RANKL/ mice were cocultured with osteo-
clast precursors from wild-type mice.25 Many hormones and
cytokines regulate stromal cell and osteoblastic cell-derived
RANKL expression. Cellular signaling mechanisms governing
PTH, vitamin D3, and IL-6 family member-induced RANKL
expression have received much of the attention because of their
role in stromal cell-derived cytokine-mediated osteoclast for-
mation.6,27,28 PTH-induced RANKL expression was shown to
be dependent on cyclic AMP binding protein (CREB) but not
c-Fos or Cbfa1.27 Conditional expression of dn mutant forms
Stat3 or gp130 in UAMS-32P stromal cells suppressed osteo-
clast-supporting activity of oncostatin M (OSM) and IL-11 but
not PTH or vitamin D3,29 indicating that Stat3 is a crucial sig-
nal in RANKL expression with IL-6 family members. Inflam-
matory mediators, including IL-1 and TNF- have been
shown to mediate their bone resorptive properties, in part,
through RANKL induction in stromal/osteoblastic cells.18,30 In
these studies, signaling mechanisms involved in IL-1 or TNF-
-induced RANKL expression indicate that p38 MAPK is a
critical component.
Consistent with work presented here, a recent study indicated
that IL-1/TNF-mediated RANKL expression requires p38 acti-
vation in stromal cells.18 Earlier studies indicate that stro-
mal/osteoblastic cells both increased or decreased OPG ex-
pression in response to IL-1 or TNF.30 Our data with ST-2 and
UAMS-32P bone marrow stromal cells is in agreement with
these earlier studies. Importantly, regardless of the cell type
studied, treatment with SB203580 decreased RANKL in both
stromal cell lines. In addition, our coculture data indicate that
blocking p38 signaling decreases IL-1 and TNF--induced os-
teoclast formation. Although these later studies did not reach
statistical significance, likely because of the long-term cultur-
ing needed after the p38 inhibitor was removed, these results
support the role of p38 inhibitors in reducing proinflammatory
cytokine-induced RANKL expression in osteolytic bone dis-
eases.
These data strongly implicate p38 as a major signaling path-
way involved in IL-1 and TNF-induced RANKL mRNA ex-
pression. An indirect activation of RANKL by these cytokines
has been supported by studies using cycloheximide to block
protein synthesis (data not shown). This would be consistent
with previous reported data suggesting that other cytokines, for
example, IL-6, provide a link between IL-1-induced RANKL
expression in bone marrow stromal cells.27,31 Other data, how-
ever, suggest that PTH directly activates RANKL expression,
and more recent data indicate that this mechanism does not re-
quire IL-6 in vivo.20,29,32 Blocking p38 signaling did not block
PTH or vitamin D3-induced RANKL expression as measured
by RT-PCR (data not shown), indicating that inflammatory cy-
tokines activate RANKL from a pathway clearly distinct from
that previously described for RANKL activation. As IL-6 may
be mediating the effects of IL-1 on RANKL expression and os-
teoclast formation, we may be observing multiple points of reg-
ulation of p38 signaling in this system. Our laboratory has
shown that IL-1 induces IL-6 in osteoblasts primarily through
an mRNA stability mechanism.33 Ongoing studies in our labo-
ratory are addressing the significance of IL-6 in LPS and IL-1-
induced osteoclastogensis.
Through Western blot analysis, membrane-bound RANKL
expression was seen to be significantly downregulated com-
pared with IL-1-stimulated stromal cells when pretreatment
with SB203580. In other studies, we were not able to measure
RANKL expression by ELISA or show that conditioned
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FIG. 5. MKK3/6-p38 signaling is required for IL-1 and TNF-
induced RANKL mRNA expression. (A) ST-2 and (B) UAMS-
32P cells were transiently transfected with MKK3dn or
MKK6dn expression plasmids for 24 h and then stimulated for
an additional 18 h with IL-1 or TNF-. Empty vector (mock
transfection) was used as controls. RT-PCR analysis was used
to assess endogenous RANKL mRNA normalized to GAPDH
and expressed as fold change relative to mock transfected con-
trol. *p  0.05, stimulated vs. MKK3dn or MKK6dn trans-
fected and stimulated cells.
A
B
medium from stromal cells supported osteoclastogenesis (data
not shown), suggesting that most stromal cell-derived RANKL
is membrane bound and not shed through enzymatic cleavage,
as reported for other RANKL-expressing cells.34,35 Thus, ex-
pression of both mRNA and protein of stromal cell-derived
RANKL was inhibited when p38 signaling was attenuated.
To understand the mechanism of p38-dependent RANKL
mRNA expression, posttranscriptional regulation was explored.
RANKL does not possess a classic AU-rich 3-UTR, a com-
mon feature of several unstable cytokine mRNAs; however,
previous studies using UAMS-32P cells indicated that PTH en-
hanced RANKL mRNA stability.27 Moreover, p38 signaling is
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FIG. 6. p38 is required for IL-1 and TNF--induced osteoclastogenesis. UAMS-32P bone marrow stromal cells were stimu-
lated with IL-1 (1 ng/mL) or TNF- (5 ng/mL) for 72 h or in the presence of SB203580 (10 M). Stromal cells were washed
extensively, and RAW264.7 macrophages were cultured with stromal cells for an additional 6 days. (A) Representative images
from 6-day coculture experiments (100) are shown. (B) Graphic representation of enumerated TRAP-positive multinucleated
formation ( three nuclei) in each culture is presented, with the mean 	 SEM data from the two independent experiments.
A
B
the major signaling mechanism linked to enhanced mRNA sta-
bility of several cytokine genes,24 including IL-1-induced 
IL-6 mRNA stability in osteoblasts.33 Surprisingly, RANKL
mRNA degradation studies performed in both ST-2 and UAMS-
32P bone marrow stromal cell lines indicated that SB203580
did not alter IL-1-induced RANKL mRNA decay rates. The
half-life of RANKL varied significantly between cell lines. The
results indicate that p38-induced RANKL expression does not
significantly involve posttranscriptional mRNA stability mech-
anisms. These findings indicate that most of the regulation must
occur through RANKL transcriptional activity.
Although the proximal 0.7 kb of the RANKL promoter con-
tains a Cbfa1/Runx2 binding site, this site was shown to be in-
sufficient to drive RANKL expression in stromal cell lines.20
Other studies using bone-derived endothelial cells have indi-
cated that transforming growth factor- (TGF-) can induce
RANKL expression through a p38/PKA-dependent mechanism
involving ATF-2/CREB within the proximal promoter.7 Al-
though two CRE sites are located in the RANKL proximal pro-
moter, TGF--induced promoter activity was stimulated only
2-fold, whereas transfection with the wt-CREB overexpression
construct greatly enhanced RANKL mRNA levels. Preliminary
promoter regulation experiments with ST-2 cells using a murine
promoter construct (1014 to 111) failed to show any regu-
lation with IL-1 or TNF- (data not shown). These data were
consistent with proximal promoter data obtained using the
700 to 111 and 7000 to 111 RANKL proximal pro-
moter constructs, where promoter activity in bone marrow stro-
mal cells was higher compared with other cell types, but no sig-
nificant regulation was observed with OSM, which increased
RANKL gene expression in bone marrow stromal cells. Col-
lectively, these data suggested that RANKL promoter regula-
tion may require additional 5 flanking elements or an intronic
sequence to mediate transcriptional activation.20
Because these data indicated that the proximal RANKL pro-
moter region was not the major target for IL-1-induced
RANKL expression, a larger segment of the 5 flanking region
of the RANKL promoter along with the entire RANKL in-
tronic/exonic sequence (minus the 3-UTR where the reporter
gene was inserted) was obtained to analyze the transcriptional
activity and responsiveness to p38-induced signals. Using this
reporter cell line (RANKL-luc), IL-1 and TNF- induced
RANKL promoter reporter activity nearly 5-fold. This fold ac-
tivation mimicked endogenous RANKL mRNA stimulation,
suggesting that within this 120-kb flanking region, or possibly
the intronic sequence of the RANKL gene, was the regulatory
element(s) required for RANKL expression. As recent data in-
dicated that TNF-mediated RANKL stimulation required a
functional IL-1 signaling system, the IL-1 response element
may be the functionally relevant target within this 120-kB re-
gion.18 Critical to these studies, we show that SB203580 can
completely abolish both IL-1 and TNF--induced RANKL-
luc expression. Rather than addressing the exact cis-acting el-
ements within this 120-kB region or intronic sequences, we fo-
cused our attention on p38-signaling intermediates that may
impact RANKL expression.
p38 MAPK is activated by phosphorylation via upstream ki-
nases, such as MKK3 and MKK6. Using dn constructs of
MKK3 and MKK6, both constructs completely blocked IL-1-
induced RANKL-luc activity. Similarly, endogenous RANKL
expression was blocked with MKK3dn and MKK6dn con-
structs, although significant levels of inhibition were not ob-
served in all experiments due, in part, to transfection efficiency
in these cells. These data confirmed p38 inhibitor data and sug-
gest that p38 is a major signaling intermediate required for
IL-1 or TNF--induced RANKL expression in stromal cells
because SB203580 is specific for p38/ isoforms and both
MKK3 and MKK6 can phosphorylate p38.36,37 Whereas
MKK6 can phosphorylate all p38 isoforms, MKK3 phosphor-
ylates only the p38 isoform.38 A constitutively active mutant
MKK3 also increased RANKL-luc activity, providing addi-
tional support the p38 MAPK pathway as a central signaling
pathway controlling RANKL expression at the distal promoter
level.
Other recent studies have focused on the RANKL 5 flank-
ing region. One recent abstract indicated that this 120-kb 5
flanking region was stimulated by cAMP in stromal/osteoblas-
tic cells and not in hepatic cells.22 Deletion analysis of this re-
gion indicated that an 8-kb region located 74 kb upstream of
the transcriptional start site was necessary for cAMP, PTH,
1,25(OH)2D3, or OSM induction. This 8-kb region was found
to be conserved across many species and, similar to other stud-
ies where some regulation was observed with the proximal pro-
moter, two conserved CRE-binding sites were found. When
these sites were mutated, cAMP responsiveness was lost. As
p38 can increase ATF-2/CREB activity, it is possible that p38
can regulate the RANKL region through this CRE-containing
8-kb conserved region. In addition, other studies suggest that
IL-1-induced p38 MAPK can activate Stat3, with delayed ki-
netics.39 Ongoing studies are pursuing the possibility that p38
may regulate RANKL regulation through an indirect mecha-
nism whereby p38 activates Stat3 to stimulate IL-6 family mem-
bers that, in a paracrine manner, feed back on the stromal/os-
teoblastic cells to induce RANKL expression.
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